PT-141 (Bremelanotide): reference dosing schedule
> Updated:
Calculate the PT-141 (Bremelanotide) dose
The calculator is already set up for PT-141 (Bremelanotide) — adjust the dose or diluent volume for your vial.
Human dosing
Searches for bremelanotide mostly ask about the on-demand dose rather than a multi-day course, so the numbers below cover how much, how often, and how far ahead of the event the dose is given in the published trials.
| Period / condition | Dose | Escalation |
|---|---|---|
| Starting (to gauge tolerability) | 0.5–1 mg subcutaneously, on demand, ≥45 min before the event | Starting dose |
| Studied regimen (Vyleesi) | 1.75 mg subcutaneously, single dose on demand | Increase if needed |
| Frequency limit | no more than 1 dose per 24 h; up to 8 doses per month | Maximum in this schedule |
A full review of the mechanism and clinical data is available in the monograph.
Practical dosing and effect details
In the two randomized RECONNECT phase 3 trials (Kingsberg and colleagues, Obstetrics & Gynecology, 2019), 1.75 mg subcutaneous bremelanotide given on demand was compared with placebo. Participants took the dose roughly 45 minutes before sexual activity rather than on a fixed daily schedule.
In that trial it was this single on-demand dose, not a course with gradual escalation, that showed a statistically significant difference from placebo on the primary endpoints (desire and distress). That sets bremelanotide apart from the daily- or weekly-schedule peptides elsewhere on this site: the effect here is tied to one administration, not to a dose accumulated over a week.
The frequency limit above (no more than one dose per 24 hours, up to 8 doses per month) reflects the bounds used in the trial rather than an arbitrary cap.
This is reference information drawn from a published trial, not a medical recommendation and not instructions for self-administration.
How to reconstitute
An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.
- 1Add the diluentUse bacteriostatic water. Example: 2 ml into a 10 mg vial.PT-141 (Bremelanotide)10 mg+ 2 mlDiluent
- 2Get the concentrationExample: 10 mg in 2 ml =PT-141 (Bremelanotide)5 mg/ml(5,000 mcg/ml)
- 3Work out the volume per doseFor example, for a 0.5 mg dose:0.5 mg = 0.1 ml= 10 u. (U-100)
This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →
Research protocols
PT-141: reference regimens
PT-141 (bremelanotide) is given subcutaneously on demand, a single dose ahead of an event rather than as a course. Generalized from clinical studies (RECONNECT) and the label of the approved product Vyleesi.
More scientific background in the PT-141 (Bremelanotide) monograph
Notes and safety
- • PT-141 (Bremelanotide) is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
PT-141 (Bremelanotide)